Breast Cancer PET-CT Scan: Uses, Procedure, Test Details, Accuracy and Report

Breast cancer is a very common disease in women. Initial assessment and suitable imaging may help address the nature and extent of the disease and be useful in determining subsequent management. Various imaging studies, ranging from mammograms to breast ultrasound, breast MRI, CT, or PET-CT imaging, may be recommended based on the patient's condition.

A PET CT scan is a combination of two scans: a PET scan and a computed tomography (CT) scan used to detect cancer. PET gives you data about tissue metabolism, and CT gives you detailed anatomical data. In the right hands, the mix can aid the doctor in diagnosing mammary cancers and searching for any spread to other parts of the body.

Molecular Diagnostics and Therapy provides sophisticated diagnostic imaging capabilities that can help doctors assess patients who are advised to have PET-CT imaging as part of their breast cancer assessment.

What Is a PET-CT Scan for Breast Cancer?

A PET-CT is one of the hybrid imaging exams. PET detects where increased metabolic activity is taking place, and CT provides information on where and what is going on. F-18 fluorodeoxyglucose (FDG) is widely used and commonly used as a tracer in PET-CT imaging for various types of cancer. FDG is a molecule similar to glucose, and regions with a higher metabolic rate could absorb larger amounts. The PET scanner can identify this activity and generate images that are fused with the CT images.

Why Is PET-CT Used in Breast Cancer?

Not all breast cancer patients need a PET-CT scan. Imaging tests are chosen by doctors according to the type and stage of cancer, any symptoms and previous test results, and the clinical question being answered. For some patients, PET-CT can be used to distinguish whether breast cancer is spread to nearby lymph nodes or further away. When applicable, it can also be used to get information that can aid physicians in determining the amount of disease and treatment. PET-CT can sometimes be performed to see how well treatment works or for patients who have a recurrence of cancer that was thought to have been cured.

When May a Breast Cancer PET-CT Be Recommended?

PET-CT may be suggested by a physician when a person's breast cancer may have spread, or if the physician is unsure about how far a breast cancer has grown. This is quite helpful in clinical or radiologic suspicion of tumor infiltration outside the breast and/or the regional lymph node area. In selected patients, a PET-CT imaging scan may also be used to evaluate a patient's response to therapy, or to search for any signs of recurrence or metastases. Judgment is based on a case-by-case basis among patients. Remember, PET-CT is not used for everyone and isn't an automatic test for women or every breast lump or new breast cancer diagnosis.

How Does a Breast Cancer PET-CT Scan Work?

Before the scan, a small dose of the radiotracer is injected through a vein. The patient rests quietly after the injection for about 30 to 60 minutes, until the tracer has been taken up by tissues and circulates. Afterwards, the patient is positioned on a special table that moves throughout the PET-CT scanner. In general, the CT images are obtained first and then the PET images. To get clear images, it is important to be absolutely still for the duration of the scan. The scanning part of the exam can last approximately 30 minutes, but the whole appointment lasts longer due to the preparation and waiting time following the tracer injection.

How Should You Prepare for a PET-CT Scan?

Preparation varies based on the type of PET-CT to be carried out. To perform an FDG PET-CT, generally patients are required to stop eating for a few hours prior to the procedure and ingest water based on the protocol standard. Before an FDG PET-CT, blood glucose (sugar) might be measured since the level of blood sugar can influence the distribution and interpretation of FDG. Special instructions for people with diabetes may be given. The healthcare provider should be alerted to any medications, medical history, recent illnesses, allergies, pregnancy, or breastfeeding. You were informed how to prepare for the examination before this by the imaging centre.

What Can a PET-CT Show in Breast Cancer?

The PET-CT can give information on the area that has a high metabolic activity, and it can demonstrate the anatomical location of the high metabolic activity. This can aid doctors in assessing the breast, the lymph nodes, and other parts for signs of cancer spread. PET gives information on metabolic activity, while the CT portion gives anatomical information. 

These findings, when put together, may be useful in understanding what may be happening elsewhere in the surgical area in the light of the known disease. But as these uptake levels rise, it doesn't necessarily indicate cancer. Increased uptake can also result from inflammation and infection. PET-CT results must then be correlated with other tests, physical exam findings, a patient's symptomology and medical history.

How Accurate Is PET-CT for Breast Cancer?

It's important to read the term PET-CT accuracy carefully. In some patients, PET-CT can offer a valuable indicator of metabolic activity and the potential level of breast cancer but isn't used in all patients or in all forms of breast cancer. There are cases of breast cancers with weaker FDG uptake. However, NCI points out that invasive lobular carcinoma typically has a lower uptake and lower sensitivity to being detected by PET than does invasive ductal carcinoma. An abnormal PET-CT scan may need further scans, further testing, or a biopsy. PET-CT should not be used as an alternative to tissue diagnosis; however, when a biopsy would be clinically indicated.

Can PET-CT Confirm Breast Cancer?

PET-CT can help identify areas of abnormal metabolic activity, but an abnormal PET-CT finding does not automatically confirm cancer. Breast cancer diagnosis may involve physical examination, mammography, ultrasound, MRI, and biopsy depending on the situation. If imaging shows a suspicious breast lesion, a biopsy may be required to determine whether it is cancerous and to identify important features of the tumour. Similarly, increased uptake in lymph nodes or other organs does not always mean that cancer has spread. Infection and inflammation can produce abnormal PET findings as well.

PET-CT for Breast Cancer Staging

Staging helps doctors understand how far breast cancer has spread. PET-CT may provide information about distant disease in selected patients and can be useful when metastatic disease is suspected. The information from PET-CT may be considered alongside biopsy results, mammography, ultrasound, MRI, CT, laboratory findings, and the patient's clinical history. The appropriate tests depend on the type and stage of breast cancer.

PET-CT After Breast Cancer Treatment

PET-CT may be used in selected situations to assess how cancer is responding to treatment or to investigate possible recurrence. Changes in metabolic activity can provide useful information, but treatment-related inflammation may also affect PET findings. Therefore, the timing of the scan and the patient's treatment history are important when interpreting the results.

Conclusion

PET - CT is a cancer imaging technique that integrates information from metabolism (PET) with anatomical information (CT). It can be useful in selected women with breast cancer to see if the disease is present, to help determine if the disease has spread, to help see how well the treatment has worked, and to help check for a recurrence if this is suspected. But PET-CT isn't a necessary test for all women with breast cancer, and it also does not diagnose the disease. 

Molecular Diagnostics and Therapy provides advanced diagnostic imaging services, including PET-CT, to support the evaluation of various cancers and other medical conditions. For patients undergoing breast cancer evaluation, PET-CT may provide useful information about metabolic activity and the possible extent of disease when it is clinically appropriate. The final interpretation should always be considered alongside biopsy results, other imaging, treatment history, and clinical findings.